REPLIGEN CORPORATION (NASDAQ:RGEN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
On November 20, 2017, Repligen Corporation (the “Company”) entered into a Transitional Services and Separation Agreement (the “Separation Agreement”) with Howard Benjamin, to which Dr.Benjamin will retire from his role as the Company’s Vice President of Business Development and cease to be an “executive officer” of the Company, effective December31, 2017 (the “Transition Start Date”), and thereafter provide services to the Company on a part-time, as needed basis through February28, 2018 (the “Separation Date”) at the direction of the Company’s Chief Executive Officer. Under the terms of the Separation Agreement, Dr.Benjamin will continue to receive his base salary and benefits now in effect through the Transition Start Date. Dr.Benjamin will continue to vest in his outstanding time-based equity awards through the Separation Date. Any equity rights that are not vested as of the Separation Date will terminate as of such date.
The above description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.
| Item 5.02. | Financial Statements and Exhibits. |
(d) Exhibits
REPLIGEN CORP ExhibitEX-10.1 2 d497198dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Personal and Confidential November 20,…To view the full exhibit click here
About REPLIGEN CORPORATION (NASDAQ:RGEN)
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies several growth factor products, Alternating Tangential Flow (ATF) System products and cell filtration products used to increase cell culture productivity during the bioproduction process. The Company has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits.
